Portal de Periódicos da CAPES

Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV)

2021; Oxford University Press; Volume: 75; Issue: 1 Linguagem: Inglês

10.1093/cid/ciab1008

1537-6591

Khadija Khan, Gila Lustig, Mallory Bernstein, Derseree Archary, Sandile Cele, Farina Karim, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Yoliswa Miya, Ntombifuthi Mthabela, Nombulelo Magula, Richard Lessells, Túlio de Oliveira, Bernadett I. Gosnell, Salim S. Abdool Karim, Nigel Garrett, Willem A. Hanekom, Linda‐Gail Bekker, Glenda Gray, Jonathan M. Blackburn, Mahomed‐Yunus S. Moosa, Alex Sigal, Adrie J. C. Steyn, Alasdair Leslie, Dirhona Ramjit, Emily Wong, Guy Harling, Henrik N. Kløverpris, Jackson Marakalala, Janet Seeley, Jennifer Giandhari, Kaylesh J Dullabh, Kennedy Nyamande, Kobus Herbst, Kimesh Naidoo, Matilda Mazibuko, Moherndran Archary, Mosa Moshabela, Nesri Padayatchi, Nigel Klein, Nikiwe Mbatha, Nokuthula Ngcobo, Nokwanda Gumede, Nokwanda Ngcobo, Philip Goulder, Prakash Jeena, Rajhmun Madansein, Ravindra K. Gupta, Rohen Harrichandparsad, Samita Singh, Thandeka Khoza, Theresa Smit, Thumbi Ndung’u, Vinod Patel, Zaza M. Ndhlovu,

Vaccine Coverage and Hesitancy

Abstract Background People living with HIV (PLWH) have been reported to have a higher risk of more severe COVID-19 disease and death. We assessed the ability of the Ad26.CoV2.S vaccine to elicit neutralizing activity against the Delta variant in PLWH relative to HIV-negative individuals. We also examined effects of HIV status and suppression on Delta neutralization response in SARS-CoV-2—infected unvaccinated participants. Methods We enrolled participants who were vaccinated through the SISONKE South African clinical trial of the Ad26.CoV2.S vaccine in healthcare workers (HCWs). PLWH in this group had well-controlled HIV infection. We also enrolled unvaccinated participants previously infected with SARS-CoV-2. Neutralization capacity was assessed by a live virus neutralization assay of the Delta variant. Results Most Ad26.CoV2.S vaccinated HCWs were previously infected with SARS-CoV-2. In this group, Delta variant neutralization was 9-fold higher compared with the infected-only group and 26-fold higher relative to the vaccinated-only group. No decrease in Delta variant neutralization was observed in PLWH relative to HIV-negative participants. In contrast, SARS-CoV-2—infected, unvaccinated PLWH showed 7-fold lower neutralization and a higher frequency of nonresponders, with the highest frequency of nonresponders in people with HIV viremia. Vaccinated-only participants showed low neutralization capacity. Conclusions The neutralization response of the Delta variant following Ad26.CoV2.S vaccination in PLWH with well-controlled HIV was not inferior to HIV-negative participants, irrespective of past SARS-CoV-2 infection. In SARS-CoV-2—infected and nonvaccinated participants, HIV infection reduced the neutralization response to SARS-CoV-2, with the strongest reduction in HIV viremic individuals.